Literature DB >> 28251815

A Bayesian sequential design with binary outcome.

Han Zhu1, Qingzhao Yu2, Donald E Mercante2.   

Abstract

Several researchers have proposed solutions to control type I error rate in sequential designs. The use of Bayesian sequential design becomes more common; however, these designs are subject to inflation of the type I error rate. We propose a Bayesian sequential design for binary outcome using an alpha-spending function to control the overall type I error rate. Algorithms are presented for calculating critical values and power for the proposed designs. We also propose a new stopping rule for futility. Sensitivity analysis is implemented for assessing the effects of varying the parameters of the prior distribution and maximum total sample size on critical values. Alpha-spending functions are compared using power and actual sample size through simulations. Further simulations show that, when total sample size is fixed, the proposed design has greater power than the traditional Bayesian sequential design, which sets equal stopping bounds at all interim analyses. We also find that the proposed design with the new stopping for futility rule results in greater power and can stop earlier with a smaller actual sample size, compared with the traditional stopping rule for futility when all other conditions are held constant. Finally, we apply the proposed method to a real data set and compare the results with traditional designs.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian clinical trial; alpha-spending functions; sequential design; stop for futility

Mesh:

Year:  2017        PMID: 28251815     DOI: 10.1002/pst.1805

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  A Bayesian Sequential Design for Clinical Trials with Time-to-Event Outcomes.

Authors:  Lin Zhu; Qingzhao Yu; Donald E Mercante
Journal:  Stat Biopharm Res       Date:  2019-07-22       Impact factor: 1.452

2.  Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).

Authors:  Rui-Fang Zhu; Yu-Lu Gao; Sue-Ho Robert; Jin-Ping Gao; Shi-Gui Yang; Chang-Tai Zhu
Journal:  J Transl Med       Date:  2020-07-06       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.